Pilot Trial of Neoadjuvant Atezolizumab in Cutaneous Melanoma

Pilot Trial of Neoadjuvant Atezolizumab in Cutaneous Melanoma

Publication date: Jul 16, 2019

The purpose of this research study is to see whether using atezolizumab before surgery is safe and does not cause side effects that delay surgery in participants with cutaneous melanoma that has not spread to other areas of the body (non-metastatic) and can be removed by surgery (resectable) but has a higher risk of coming back after surgery (high-risk).

Concepts Keywords
Antigen Clinical medicine
Biopsy RTT
Blood Medicine
Cancer Back surgery
CD4 Surgery
Contraceptive Melanomas
Cooperative Group HIV
Failure Rate Cutaneous Melanoma
Hepatitis Health
Heterosexual Melanoma
Histologically Cancer
Immune System Atezolizumab
Immunodeficiency Sentinel lymph node
Informed Consent Cancer immunotherapy
Ligand Uveal melanoma
Melanoma
Melanomas
Metastatic
Methodist Hospital
Mitoses
Nave
Organ
Protocol
Resection
Retroviral
Surgical Oncologist
Test Screening
Viral Load
Virus

Semantics

Type Source Name
gene UNIPROT PNMA2
drug DRUGBANK Aspartame
gene UNIPROT PDPN
disease DOID Cancer
disease MESH Cancer
disease DOID Cutaneous Melanoma
drug DRUGBANK Atezolizumab
gene UNIPROT EGR3
gene UNIPROT CD4
disease MESH viral load
drug DRUGBANK Hepatitis B Vaccine (Recombinant)
gene UNIPROT NR4A2
gene UNIPROT ALG3
disease MESH Melanoma
disease DOID Melanoma
pathway BSID Melanoma

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *